Abstract

Rapid, inexpensive, robust diagnostics are essential to control the spread of infectious diseases. Current state of the art diagnostics are highly sensitive and specific, but slow, and require expensive equipment. Here we report the development of a molecular diagnostic test for SARS-CoV-2 based on an enhanced recombinase polymerase amplification (eRPA) reaction. eRPA has a detection limit on patient samples down to 5 viral copies, requires minimal instrumentation, and is highly scalable and inexpensive. eRPA does not cross-react with other common coronaviruses, does not require RNA purification, and takes ~45 min from sample collection to results. eRPA represents a first step toward at-home SARS-CoV-2 detection and can be adapted to future viruses within days of genomic sequence availability.

Current state-of-the-art diagnostics for infectious diseases are sensitive but require extensive equipment. Here the authors develop an enhanced recombinase polymerase amplification reaction for SARS-CoV-2 that allows for inexpensive and rapid testing with minimal equipment.

Details

Title
An enhanced isothermal amplification assay for viral detection
Author
Qian, Jason 1 ; Boswell, Sarah A 2   VIAFID ORCID Logo  ; Chidley, Christopher 3   VIAFID ORCID Logo  ; Zhi-xiang, Lu 2   VIAFID ORCID Logo  ; Pettit, Mary E 4   VIAFID ORCID Logo  ; Gaudio, Benjamin L 2 ; Fajnzylber Jesse M 5 ; Ingram, Ryan T 4   VIAFID ORCID Logo  ; Ward, Rebecca H 4 ; Li, Jonathan Z 6   VIAFID ORCID Logo  ; Springer, Michael 7   VIAFID ORCID Logo 

 Harvard Medical School, Department of Systems Biology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Laboratory of Systems Pharmacology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Biological and Biomedical Sciences Program, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Harvard Medical School, Department of Systems Biology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Laboratory of Systems Pharmacology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Harvard Medical School, Laboratory of Systems Pharmacology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Harvard Medical School, Department of Systems Biology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Harvard Medical School, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Harvard Medical School, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Massachusetts Consortium on Pathogen Readiness, Boston, USA (GRID:grid.38142.3c) 
 Harvard Medical School, Department of Systems Biology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Laboratory of Systems Pharmacology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Massachusetts Consortium on Pathogen Readiness, Boston, USA (GRID:grid.38142.3c) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2471574310
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.